๐ฉธ๐ Todayโs questions!
Swipe to see the answers and explanations!
#SmolderingMultipleMyeloma #SMM #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #HemeHub

๐ฉธ๐ Todayโs questions!
Swipe to see the answers and explanations!
#SmolderingMultipleMyeloma #SMM #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #HemeHub
๐ฉธ Facts about Smoldering Multiple Myeloma:
The immune microenvironment as a gatekeeper of progression, protective anti-SOX2 T-cell responses, early immune dysregulation, loss of stem-like TCF1/7+ T cells, and immune normalization following therapy.
๐ญ๐ฏ Todayโs questions!
Swipe to see the answers and explanations!
#SmolderingMultipleMyeloma #SMM #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #MRD #ASCT #StemCellTransplant #APOBEC #HemeHub
๐งฌ Facts about Smoldering Multiple Myeloma:
Genomic MM vs. genomic MGUS, genomic drivers of progression, genomic biomarkers of non-progressors, the Genomic Scar Score (GSS), and the continuous genomic gradient from MGUS to SMM to MM.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology
๐ก๐ Todayโs questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
๐งฌ Facts about Smoldering Multiple Myeloma:
Genomic drivers of progression, APOBEC and AID activity, genomic risk scoring, and MAF/MAFB translocations.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
๐๐Todayโs questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #Immunology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
๐ฉธ Facts about Smoldering Multiple Myeloma:
The PANGEA risk model, key progression biomarkers, limitations of static risk models, and progression risk across low-, intermediate-, and high-risk SMM.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #HemeHub
๐ฏTodayโs questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #Genomics #HemeHub
๐ฉธ Facts about Smoldering Multiple Myeloma:
Key SMM risk models include Mayo 2008, PETHEMA, IMWG 20/2/20, cytogenetic risk refinement, and the MGUS-like phenotype.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #HemeHub
๐๐กTodayโs questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub #Daratumumab #AQUILA #CENTAURUS
๐ฉธ Facts about Smoldering Multiple Myeloma:
SLIM-CRAB criteria, precursor stages, immunoparesis, evolving biomarkers, and circulating tumor cells all play a role in assessing SMM progression risk.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #HemeHub
๐ฉธ Facts about Smoldering Multiple Myeloma:
Historical origins, IMWG diagnostic criteria, population prevalence, natural progression risk, and the biological heterogeneity of SMM, including its distinction between MGUS-like and myeloma-like disease.
๐๐ฏFirst clinical questions of the month!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Myeloma #PlasmaCellDisorders #MGUS #IMWG #Hematology #HemeOnc #Oncology #ClinicalHematology #MedicalEducation #MedEd #HemeHub
๐๐ฎ๐ซ ๐ฆ๐จ๐๐ฎ๐ฅ๐ ๐จ๐ง: ๐๐ฎ๐ฅ๐ญ๐ข๐ฉ๐ฅ๐ ๐๐ฒ๐๐ฅ๐จ๐ฆ๐ ๐๐ง๐ ๐๐จ๐ง๐จ๐๐ฅ๐จ๐ง๐๐ฅ ๐๐๐ฆ๐ฆ๐จ๐ฉ๐๐ญ๐ก๐ฒ ๐จ๐ ๐๐ง๐๐๐ญ๐๐ซ๐ฆ๐ข๐ง๐๐ ๐๐ข๐ ๐ง๐ข๐๐ข๐๐๐ง๐๐ ๐ข๐ฌ ๐ง๐จ๐ฐ ๐๐ฏ๐๐ข๐ฅ๐๐๐ฅ๐ ๐ญ๐จ ๐๐ฅ๐ฅ ๐ฆ๐๐ฆ๐๐๐ซ๐ฌ. ๐
Not a member? ๐ค Find out more on how to join: fmpe.org/our-program/...
#MultipleMyeloma #MGUS #SmolderingMultipleMyeloma #PrimaryCare #FamilyMedicine #MedicalEducation